VCs Supported UK Biotech In 2024’s Tricky Funding Environment

 
• By Andrew McConaghie
  
The UK remains the best capitalized European biotech sector but no IPOs and few licensing deals meant its companies had limited funding options in 2024. (Shutterstock)

More from Financing

More from Start-Ups & SMEs